Literature DB >> 6796194

Magnitude and duration of hyperactivity following neonatal 6-hydroxydopamine is related to the extent of brain dopamine depletion.

F E Miller, T G Heffner, C Kotake, L S Seiden.   

Abstract

This experiment examined the relationship between the extent of brain dopamine (DA) neuron destruction in the neonatal rat and locomotor hyperactivity during subsequent development. Brain DA neurons were destroyed selectively in neonatal rats by intraventricular injections of 6-hydroxydopamine (6-OHDA) following desmethylimipramine (DMI) pretreatment of both days 3 and 6 of life. Groups of rats received total doses of 50, 70, 100 or 200 microgram of 6HDA or the vehicle solution. Each group of rats given 6-OHDA displayed 3- to 5-fold increases in locomotor activity relative to vehicle control rats on days 16 and 18 of life. Rats given 50 or 70 microgram of 6-OHDA displayed hyperactivity that diminished during days 18-32 of life, approaching the level of activity seen in vehicle-treated rats. It contrast, rats given 100 or 200 microgram of 6-OHDA displayed consistently high levels of locomotion during days 18-32 of life. When tested as adults (days 55-66 of life) only those rats given 200 micrograms of 6-OHDA as neonates continued to display locomotor hyperactivity. The extent of 6-OHDA-induced depletion of DA was proportional to the magnitude of locomotor hyperactivity seen during neonatal life. Brain DA was depleted to the greatest extent in rats which displayed permanent hyperactivity. Regardless of the extent of depletion of brain DA, adult rats given intraventricular injections of 125, 200 or 275 micrograms of 6-OHDA at 48 days of age (following pargyline and DMI pretreatment) displayed no significant change in locomotor activity. These results indicate that the magnitude and duration of locomotor hyperactivity seen following neonatal 6-OHDA injections are correlated with the extent of loss of central DA neurons and suggest that brain DA projections exert important influences on the ontogeny of normal locomotion.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6796194     DOI: 10.1016/0006-8993(81)90750-2

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  22 in total

Review 1.  Neurodegeneration and neuroprotection in Parkinson disease.

Authors:  Stanley Fahn; David Sulzer
Journal:  NeuroRx       Date:  2004-01

2.  Altered Corticostriatal Connectivity and Exploration/Exploitation Imbalance Emerge as Intermediate Phenotypes for a Neonatal Dopamine Dysfunction.

Authors:  Barbara Y Braz; Gregorio L Galiñanes; Irene R E Taravini; Juan E Belforte; M Gustavo Murer
Journal:  Neuropsychopharmacology       Date:  2015-04-15       Impact factor: 7.853

3.  Differential effects of prenatal exposure to phenobarbital on the behaviour and neurochemistry of CBA and C57BL/6J mice.

Authors:  S K Sedowofia; J Innes; A Peter; E Alleva; A Manning; R M Clayton
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

Review 4.  Animal models to guide clinical drug development in ADHD: lost in translation?

Authors:  Jeffery R Wickens; Brian I Hyland; Gail Tripp
Journal:  Br J Pharmacol       Date:  2011-10       Impact factor: 8.739

Review 5.  Functional Interplay between Dopaminergic and Serotonergic Neuronal Systems during Development and Adulthood.

Authors:  Vera Niederkofler; Tedi E Asher; Susan M Dymecki
Journal:  ACS Chem Neurosci       Date:  2015-03-18       Impact factor: 4.418

Review 6.  A controlled study of Tourette syndrome. VII. Summary: a common genetic disorder causing disinhibition of the limbic system.

Authors:  D E Comings
Journal:  Am J Hum Genet       Date:  1987-11       Impact factor: 11.025

7.  DNA microarray unravels rapid changes in transcriptome of MK-801 treated rat brain.

Authors:  Yuka Kobayashi; Sofya P Kulikova; Junko Shibato; Randeep Rakwal; Hiroyuki Satoh; Didier Pinault; Yoshinori Masuo
Journal:  World J Biol Chem       Date:  2015-11-26

Review 8.  Pharmacological models of ADHD.

Authors:  R M Kostrzewa; J P Kostrzewa; R A Kostrzewa; P Nowak; R Brus
Journal:  J Neural Transm (Vienna)       Date:  2007-11-12       Impact factor: 3.575

9.  Unilateral neonatal intracerebroventricular 6-hydroxydopamine administration in rats: I. Effects on spontaneous and drug-induced rotational behaviour and on postmortem monoamine levels.

Authors:  J Luthman; M Herrera-Marschitz; E Lindqvist
Journal:  Psychopharmacology (Berl)       Date:  1994-12       Impact factor: 4.530

10.  Functional deficits following neonatal dopamine depletion and isolation housing: circular water maze acquisition under pre-exposure conditions and motor activity.

Authors:  Trevor Archer; Tomás Palomo; Anders Fredriksson
Journal:  Neurotox Res       Date:  2002 Aug-Sep       Impact factor: 3.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.